Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

As part of World Cancer Day 2022 we are diving into one of the department's most impactful historical and modern contributions to the field of cancer science and treatment.

A discovery so significant that it warranted a Nobel prize: Sir Peter Ratcliffe is famed for his work on oxygen deprivation (hypoxia) and subsequent cellular responses.

Cancers have unique microenvironments, which they must overcome in order to grow rapidly and uncontrollably. By understanding these conditions and how they come about, clinicians and researchers can strive to develop new drugs to reverse or suppress these pathways.

During his time in Oxford’s Nuffield Department of Medicine, Sir Peter discovered that a specific hormone, known as EPO, was involved in the production of blood cells in response to low oxygen levels in the kidneys. The underlying mechanism behind this process was later applied to cancer, and explained how cancers could create new blood vessels to sustain their fast and uncontrolled growth. This discovery was so significant, he was awarded the Nobel Prize in Medicine in 2019. Ratcliffe’s work into EPO has paved the way for the development of new drugs to improve the efficacy of cancer treatments.

Continuing this important work into tumour microenvironments, the Oxford ARCADIAN project is now investigating how common antimalarial drug Atovaquone can help to reduce the hypoxic environment of tumours and improve the efficacy of treatments such as radiation.

Similar stories

Malaria booster vaccine continues to meet WHO-specified 75% efficacy goal

Researchers from the NDM's Jenner Institute and their partners have today reported new findings from their Phase 2b trial following the administration of a booster dose of the candidate malaria vaccine, R21/Matrix-M™ – which previously demonstrated high-level efficacy of 77% over the following 12 months in young west African children in 2021.

Study raises hope of pre-school type 1 diabetes screening programme

Researchers in Oxford have launched the first UK study in the general population to test for early markers of type 1 diabetes before children develop symptoms or need insulin.

New monkeypox treatment trialled at Oxford University

The team behind the world-leading RECOVERY trial of COVID-19 treatments are leading a new study investigating a potential treatment for people who have been diagnosed with monkeypox. The National Institute for Health and Care Research (NIHR) has commissioned and funded the study and the first patients have now been recruited.

First clinical trial data for new rabies vaccine candidate demonstrates promising immune response and safety

Researchers from the University of Oxford have today reported new findings from a Phase 1 clinical trial studying the immune response and safety of their newly-developed single shot rabies vaccine, ChAdOx2 RabG.

Largest genetic study of pleural infection reveals complex nature of common disease

A new genetic study of the bacteria that cause pleurisy has shown most cases involve more than one type of bacterium, and revealed which bacterial combinations cause the most serious infections.

RECOVERY trial shows Baricitinib reduces deaths in patients hospitalised with COVID-19

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial has demonstrated that baricitinib, an anti-inflammatory treatment normally used to treat rheumatoid arthritis, reduces the risk of death when given to hospitalised patients with severe COVID-19.